The Los Angeles Times (7/15, Roan) reports that "a phase-three study of more than 3,000 obese or overweight adults showed that those taking the experimental compound lorcaserin lost more weight after one year than people taking a placebo pill." Researchers found that "just over 47% of the people taking" Arena Pharmaceuticals' "lorcaserin lost 5% or more of their body weight, compared to 20.3% of people in the placebo group." The research, published "in the New England Journal of Medicine, also showed that lorcaserin produced slight improvements in blood pressure, heart rate, cholesterol, and insulin resistance."
Bloomberg News (7/15, reports that "An FDA advisory panel is scheduled to review lorcaserin on Sept. 16, Arena said." MedPage Today (7/14, Neale) also covered the story.
